RT Journal Article
T1 Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
A1 Berzosa Sánchez, Arantxa
A1 Guillén Garde, Sara
A1 Epalza Ibarrondo, Cristina
A1 Escosa García, Luis
A1 Navarro Gómez, María Luisa
A1 Prieto Tato, Luis Manuel
A1 Sanz Costa, Talía
A1 Jiménez De Ory, Santiago
A1 Montes Mota, Marina
A1 Abad Torreblanca, Raquel
A1 Vázquez Moreno, Julio A.
A1 Serrano García, Irene
A1 Ramos Amador, José Tomás
AB Background: Children and adolescents living with HIV (CALHIV) are at high risk of meningococcal infections and may present lower immune responses to vaccines. The objectives of this study were to assess the immunogenicity of the quadrivalent Men ACWY-TT vaccine (Nimenrix®) in CALHIV after a two-dose schedule and to describe possible HIV-related factors that may affect the immunogenic response. Methods: A multicenter prospective study was designed, including CALHIV followed in five hospitals in Madrid, between 2019 and 2021. Two doses of the Men ACWY-TT vaccine were administered. Serum bactericidal antibody (SBA) assays using rabbit complement (rSBA) against serogroups C, W, and Y were used to determine seroprotection and vaccine response (the proportion achieving a putative protective titer of ≥eight or a ≥four-fold rise in titer from baseline). Serum was collected at baseline, and at 3 and 12 months after vaccination. Results: There were 29 CALHIV included, 76% of whom were perinatally infected. All were receiving TAR and presented a good immunovirological and clinical status overall. At baseline, 45% of CALHIV had seroprotective titers to at least one serogroup, with individual seroprotection rates of 24%, 28%, and 32% against C, W, and Y, respectively. After a two-dose schedule, vaccine response was 83% for each serogroup, eliciting a vaccine response to all serogroups in 69% of them. One year after vaccination, 75% of CALHIV maintained seroprotective titers against the C serogroup, and 96% against W and Y. None of the HIV-related characteristics analyzed could predict vaccine response or antibody duration. Conclusions: CALHIV who received effective TAR and presented a good immuno-virological situation achieved an appropriate vaccine response after two doses of the Men ACWY-TT vaccine, and antibody-mediated protection against serogroups C, W, and Y was maintained in more than 70% of the patients one year after vaccination.
PB MDPI
YR 2023
FD 2023-12-23
LK https://hdl.handle.net/20.500.14352/104918
UL https://hdl.handle.net/20.500.14352/104918
LA eng
NO Berzosa A, Guillen S, Epalza C, Escosa L, Navarro ML, Prieto LM, et al. Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV. Microorganisms 2023;12:30. https://doi.org/10.3390/microorganisms12010030.
NO 2023 Descuento MDPI
NO Familia Alonso Foundation
NO Instituto de Salud Carlos III
NO Spanish AIDS Research Network
DS Docta Complutense
RD 10 abr 2025